Posterior reversible encephalopathy syndrome across 22 VEGF-pathway inhibitors in the FDA adverse event reporting system: reporting patterns and reporting-interval characteristics
ObjectivesPosterior reversible encephalopathy syndrome (PRES) is a rare but potentially severe complication of VEGF-pathway inhibition. A recent FAERS analysis supported PRES as a probable class effect of angiogenesis inhibitors but found no association with continuous VEGFR affinity, did not formal...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2026-07-01
|
| Serie: | Frontiers in Pharmacology |
| Soggetti: | |
| Accesso online: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1887454/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|